Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.23 Insider Own30.69% Shs Outstand38.35M Perf Week2.39%
Market Cap19.34M Forward P/E- EPS next Y-1.26 Insider Trans0.79% Shs Float26.77M Perf Month-38.03%
Income-47.53M PEG- EPS next Q-0.31 Inst Own26.40% Short Float / Ratio2.65% / 5.39 Perf Quarter-62.35%
Sales0.00M P/S- EPS this Y1.92% Inst Trans3.19% Short Interest0.71M Perf Half Y-67.06%
Book/sh0.64 P/B0.79 EPS next Y1.37% ROA-63.95% Target Price8.50 Perf Year-74.06%
Cash/sh1.63 P/C0.31 EPS next 5Y- ROE-97.17% 52W Range0.44 - 2.47 Perf YTD-65.71%
Dividend- P/FCF- EPS past 5Y51.91% ROI-158.38% 52W High-79.73% Beta0.90
Dividend %- Quick Ratio1.77 Sales past 5Y122.02% Gross Margin- 52W Low13.80% ATR0.07
Employees32 Current Ratio1.77 Sales Q/Q- Oper. Margin0.00% RSI (14)39.18 Volatility11.34% 12.56%
OptionableYes Debt/Eq0.85 EPS Q/Q30.79% Profit Margin- Rel Volume1.81 Prev Close0.49
ShortableYes LT Debt/Eq0.00 EarningsNov 09 BMO Payout- Avg Volume131.60K Price0.50
Recom1.00 SMA20-6.55% SMA50-24.76% SMA200-59.84% Volume238,249 Change2.39%
Date Action Analyst Rating Change Price Target Change
Feb-01-22Initiated RBC Capital Mkts Outperform $10
May-03-21Initiated H.C. Wainwright Buy $35
Apr-26-21Initiated SVB Leerink Outperform $18
Mar-25-21Initiated Evercore ISI Outperform $45
Dec-04-23 08:30AM
Nov-09-23 08:30AM
Nov-07-23 04:15PM
Oct-04-23 07:00AM
Sep-05-23 09:00AM
04:05PM Loading…
Aug-18-23 04:05PM
Aug-14-23 08:00AM
Aug-08-23 08:30AM
Aug-07-23 07:30AM
Jun-28-23 08:00AM
May-31-23 04:15PM
May-17-23 09:50AM
May-11-23 04:05PM
May-08-23 04:05PM
May-02-23 04:05PM
04:30PM Loading…
Apr-19-23 04:30PM
Mar-13-23 04:05PM
Mar-08-23 04:05PM
Feb-07-23 04:05PM
Jan-19-23 08:30AM
Jan-08-23 01:00PM
Nov-30-22 06:10PM
Nov-21-22 05:08PM
Nov-14-22 04:41PM
Nov-10-22 04:05PM
Nov-02-22 04:05PM
Sep-19-22 04:30PM
Sep-07-22 09:00AM
Aug-16-22 04:15PM
09:00AM Loading…
Aug-11-22 09:00AM
Aug-09-22 08:30AM
Aug-01-22 08:19AM
Jun-13-22 04:15PM
Jun-02-22 08:30AM
Jun-01-22 04:15PM
May-23-22 08:00AM
May-13-22 04:05PM
May-11-22 04:05PM
May-10-22 04:05PM
Apr-20-22 11:58AM
Apr-07-22 10:13AM
Mar-18-22 04:10PM
Mar-09-22 04:30PM
Feb-22-22 11:35AM
Feb-10-22 09:00AM
Feb-08-22 09:48AM
Jan-31-22 08:30AM
Jan-04-22 09:00AM
Dec-16-21 08:30AM
Dec-13-21 07:15PM
Nov-29-21 08:00AM
Nov-10-21 08:00AM
Nov-05-21 09:00AM
Nov-04-21 09:00AM
Nov-01-21 04:05PM
Oct-06-21 08:00AM
Sep-07-21 08:00AM
Aug-23-21 08:00AM
Aug-16-21 08:00AM
Aug-12-21 08:00AM
Jul-21-21 08:00AM
Jul-06-21 08:00AM
Jun-28-21 08:00AM
Jun-01-21 08:00AM
May-25-21 07:46AM
May-18-21 04:05PM
May-12-21 04:05PM
Apr-29-21 06:01AM
Apr-08-21 08:00AM
Mar-23-21 08:00AM
Mar-11-21 08:00AM
Mar-04-21 08:00AM
Mar-03-21 08:00AM
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rothera MarkPresident and CEODec 01Buy0.4947,90623,627100,000Dec 04 04:54 PM
Rothera MarkPresident and CEONov 30Buy0.4952,09425,73452,094Dec 04 04:54 PM
Chevallard Daniel R.CFO and COONov 28Sale0.503,7201,86098,822Nov 28 07:06 PM
Chevallard Daniel R.CFO and COONov 25Option Exercise0.006,8890102,542Nov 28 07:06 PM
ROYSTON IVORDirectorNov 25Option Exercise0.0025,2190738,865Nov 28 07:03 PM
Pomerantz RogerDirectorNov 25Option Exercise0.009,034090,341Nov 28 07:01 PM
Chevallard Daniel R.CFO and COOAug 28Sale1.453,5125,09295,653Aug 29 06:47 PM
Chevallard Daniel R.CFO and COOAug 25Option Exercise0.006,888099,165Aug 29 06:47 PM
ROYSTON IVORDirectorAug 25Option Exercise0.0025,2190713,646Aug 29 06:52 PM
Pomerantz RogerDirectorAug 25Option Exercise0.009,034081,307Aug 29 06:49 PM
Chevallard Daniel R.CFO and COOMay 25Option Exercise0.006,889095,912May 26 07:29 PM
ROYSTON IVORDirectorMay 25Option Exercise0.0025,2190688,427May 26 07:32 PM
Pomerantz RogerDirectorMay 25Option Exercise0.009,035072,273May 26 07:30 PM
Chevallard Daniel R.CFO and COOMay 25Sale1.423,6355,16092,277May 26 07:29 PM
Chevallard Daniel R.CFO and COOFeb 27Sale1.683,5996,05189,023Feb 28 06:22 PM
Rojkjaer LisaChief Medical OfficerFeb 27Sale1.682,1563,62548,087Feb 28 06:28 PM
Pomerantz RogerDirectorFeb 25Option Exercise0.009,034063,238Feb 28 06:25 PM
Chevallard Daniel R.CFO and COOFeb 25Option Exercise0.006,889092,622Feb 28 06:22 PM
ROYSTON IVORDirectorFeb 25Option Exercise0.0025,2190663,208Feb 28 06:30 PM
Rojkjaer LisaChief Medical OfficerFeb 25Option Exercise0.004,127050,243Feb 28 06:28 PM